Stereotactic Body Radiotherapy for Metastatic Lung Cancer as Oligo-Recurrence: An Analysis of 42 Cases
Purpose. To investigate the outcome and toxicity of stereotactic body radiotherapy (SBRT) in patients with oligo-recurrence cancer in the lung (ORCL). Methods and Materials. A retrospective review of 42 patients with ORCL who underwent SBRT in our two hospitals was conducted. We evaluated the outco...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Pulmonary Medicine |
| Online Access: | http://dx.doi.org/10.1155/2012/454107 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562593907081216 |
|---|---|
| author | Wataru Takahashi Hideomi Yamashita Yuzuru Niibe Kenshiro Shiraishi Kazushige Hayakawa Keiichi Nakagawa |
| author_facet | Wataru Takahashi Hideomi Yamashita Yuzuru Niibe Kenshiro Shiraishi Kazushige Hayakawa Keiichi Nakagawa |
| author_sort | Wataru Takahashi |
| collection | DOAJ |
| description | Purpose. To investigate the outcome and toxicity of stereotactic body radiotherapy (SBRT) in patients with oligo-recurrence cancer in the lung (ORCL).
Methods and Materials. A retrospective review of 42 patients with ORCL who underwent SBRT in our two hospitals was conducted. We evaluated the outcome and adverse effects after SBRT for ORCL. Results. All patients finished their SBRT course without interruptions of toxicity reasons. The median follow-up period was 20 months (range, 1–90 months). The 2-year local control rate and overall survival were 87% (95% CI, 75–99%) and 65% (95% CI, 48–82%). As for prognostic factor, the OS of patients with a short disease-free interval (DFI) months, between the initial therapy and SBRT for ORCL, was significantly worse than the OS of long DFI months (). The most commonly observed late effect was radiation pneumonitis. One patient had grade 4 gastrointestinal toxicity (perforation of gastric tube). No other ≧ grade 3 acute and late adverse events occurred. There were no treatment-related deaths during this study.
Conclusions.
In patients with ORCL, radical treatment with SBRT is safe and provides a chance for long-term survival by offering favorable local control. |
| format | Article |
| id | doaj-art-39b0d54f8a444926b63c97ac429a6d78 |
| institution | Kabale University |
| issn | 2090-1836 2090-1844 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Medicine |
| spelling | doaj-art-39b0d54f8a444926b63c97ac429a6d782025-02-03T01:22:13ZengWileyPulmonary Medicine2090-18362090-18442012-01-01201210.1155/2012/454107454107Stereotactic Body Radiotherapy for Metastatic Lung Cancer as Oligo-Recurrence: An Analysis of 42 CasesWataru Takahashi0Hideomi Yamashita1Yuzuru Niibe2Kenshiro Shiraishi3Kazushige Hayakawa4Keiichi Nakagawa5Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, JapanDepartment of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, JapanDepartment of Radiology and Radiation Oncology, Kitasato Universtiy, Kanagawa 252-0374, JapanDepartment of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, JapanDepartment of Radiology and Radiation Oncology, Kitasato Universtiy, Kanagawa 252-0374, JapanDepartment of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, JapanPurpose. To investigate the outcome and toxicity of stereotactic body radiotherapy (SBRT) in patients with oligo-recurrence cancer in the lung (ORCL). Methods and Materials. A retrospective review of 42 patients with ORCL who underwent SBRT in our two hospitals was conducted. We evaluated the outcome and adverse effects after SBRT for ORCL. Results. All patients finished their SBRT course without interruptions of toxicity reasons. The median follow-up period was 20 months (range, 1–90 months). The 2-year local control rate and overall survival were 87% (95% CI, 75–99%) and 65% (95% CI, 48–82%). As for prognostic factor, the OS of patients with a short disease-free interval (DFI) months, between the initial therapy and SBRT for ORCL, was significantly worse than the OS of long DFI months (). The most commonly observed late effect was radiation pneumonitis. One patient had grade 4 gastrointestinal toxicity (perforation of gastric tube). No other ≧ grade 3 acute and late adverse events occurred. There were no treatment-related deaths during this study. Conclusions. In patients with ORCL, radical treatment with SBRT is safe and provides a chance for long-term survival by offering favorable local control.http://dx.doi.org/10.1155/2012/454107 |
| spellingShingle | Wataru Takahashi Hideomi Yamashita Yuzuru Niibe Kenshiro Shiraishi Kazushige Hayakawa Keiichi Nakagawa Stereotactic Body Radiotherapy for Metastatic Lung Cancer as Oligo-Recurrence: An Analysis of 42 Cases Pulmonary Medicine |
| title | Stereotactic Body Radiotherapy for Metastatic Lung Cancer as Oligo-Recurrence: An Analysis of 42 Cases |
| title_full | Stereotactic Body Radiotherapy for Metastatic Lung Cancer as Oligo-Recurrence: An Analysis of 42 Cases |
| title_fullStr | Stereotactic Body Radiotherapy for Metastatic Lung Cancer as Oligo-Recurrence: An Analysis of 42 Cases |
| title_full_unstemmed | Stereotactic Body Radiotherapy for Metastatic Lung Cancer as Oligo-Recurrence: An Analysis of 42 Cases |
| title_short | Stereotactic Body Radiotherapy for Metastatic Lung Cancer as Oligo-Recurrence: An Analysis of 42 Cases |
| title_sort | stereotactic body radiotherapy for metastatic lung cancer as oligo recurrence an analysis of 42 cases |
| url | http://dx.doi.org/10.1155/2012/454107 |
| work_keys_str_mv | AT watarutakahashi stereotacticbodyradiotherapyformetastaticlungcancerasoligorecurrenceananalysisof42cases AT hideomiyamashita stereotacticbodyradiotherapyformetastaticlungcancerasoligorecurrenceananalysisof42cases AT yuzuruniibe stereotacticbodyradiotherapyformetastaticlungcancerasoligorecurrenceananalysisof42cases AT kenshiroshiraishi stereotacticbodyradiotherapyformetastaticlungcancerasoligorecurrenceananalysisof42cases AT kazushigehayakawa stereotacticbodyradiotherapyformetastaticlungcancerasoligorecurrenceananalysisof42cases AT keiichinakagawa stereotacticbodyradiotherapyformetastaticlungcancerasoligorecurrenceananalysisof42cases |